Exelixis Inc Operating Leases, Rent Expense
Exelixis Inc (EXEL) reported Operating Leases, Rent Expense of $3.94 million for the 12-month period ending 2017-12-29, per its 10-K filed 2020-02-25.
Discontinued › Expense Statement › Operating Expenses
us-gaap:LeaseAndRentalExpense · last filed 2020-02-25
- Exelixis Inc operating leases, rent expense for the quarter ending 2017-09-30 was $1.22M, a 38.39% decline year-over-year.
- Exelixis Inc operating leases, rent expense for the quarter ending 2017-06-30 was $1.49M, a 53.26% decline year-over-year.
- Exelixis Inc operating leases, rent expense for the quarter ending 2016-09-30 was $1.97M.
- Exelixis Inc operating leases, rent expense for the quarter ending 2016-06-30 was $3.19M.
- Exelixis Inc operating leases, rent expense for fiscal 2017 was $3.94M, a 59.24% decline from fiscal 2016.
- Exelixis Inc operating leases, rent expense for fiscal 2016 was $9.68M, a 30.60% decline from fiscal 2016.
- Exelixis Inc operating leases, rent expense for fiscal 2016 was $13.94M.
| Period end | Operating Leases, Rent Expense 3 month | Operating Leases, Rent Expense 6 month | Operating Leases, Rent Expense 9 month | Operating Leases, Rent Expense 12 month | Operating Leases, Rent Expense 12 month as first filed |
|---|---|---|---|---|---|
| 2017-12-29 | $3.94M 10-K · filed 2020-02-25 | $6.16M 10-K · filed 2018-02-26 | |||
| 2017-09-30 | $1.22M 10-Q · filed 2017-11-01 | $2.71M derived: sum of 2 quarters · filed 2017-11-01 | $4.99M 10-Q · filed 2017-11-01 | ||
| 2017-06-30 | $1.49M 10-Q · filed 2017-08-02 | $3.77M 10-Q · filed 2017-08-02 | |||
| 2016-12-30 | $9.68M 10-K · filed 2018-02-26 | ||||
| 2016-09-30 | $1.97M 10-Q · filed 2017-11-01 | $5.17M derived: sum of 2 quarters · filed 2017-11-01 | $7.42M 10-Q · filed 2017-11-01 | ||
| 2016-06-30 | $3.19M 10-Q · filed 2017-08-02 | $5.45M 10-Q · filed 2017-08-02 | |||
| 2016-01-01 | $13.94M 10-K · filed 2018-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |